
Novel Internet-Based Interventions to Reduce Sexual Risk Among Men Who Have Sex With Men
HIV InfectionsThe purpose of this study is to develop and test the efficacy of online HIV risk reduction interventions among men who have sex with men.

Bone Mineral Density Substudy - An Ancillary Study to MTN-003
HIV InfectionsThe MTN-003 HIV prevention study include the use of microbicides, substances that kill microbes, and tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) - oral, FDA-approved, anti-HIV drugs. The purpose of this study is to determine if taking daily TDF and FTC/TDF as a part of the study MTN-003 has an effect on bone mineral density (BMD).

Cohort Study of HIV-1 Incidence Among Clients of the Thai Red Cross AIDS Research Center, Bangkok,...
HIV InfectionsThe purpose of this study is to assess populations in Thailand at high risk for HIV-1 infection for potential efficacy trials of candidate HIV vaccines to include: assess incidence of HIV-1 and volunteer retention describe early viral load and CD4 counts assess participant willingness to participate in HIV vaccine efficacy trials and other HIV prevention trials describe volunteer risk behavior

Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women
HIV InfectionsThe purpose of this research study is to determine how much raltegravir gets into the male and female genital tract.

Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral...
HIV InfectionProspective study to evaluate the potential persistent viral effect of raltegravir in 20 treatment experienced HIV patients with incomplete viral suppression

Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV
HIV InfectionsSixty HIV participants will be enrolled and stratified by PBMC HIV DNA levels, either high (greater than or equal to 5000 copies/106 cells) or low (less than 5000 copies/106 cells). Individuals will be enrolled into each group until filled. Screening PBMC HIV DNA levels will be performed at SEARCH in real-time with less than one-week turn around time. All individuals will intend to initiate ARV due to meeting MOPH guidelines for such. The protocol team will work with the primary care physician to facilitate initiation of standard ARV care; however, initiation of ARV is not a requirement of the study and ARV will not be provided by the study.

Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men
HIV InfectionCardiovascular Risk1 moreThe purpose of this study is to examine the postprandial (anytime after a meal) effect of different dietary fats on endothelial function in HIV-infected and HIV-uninfected men.

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
HIV InfectionThe U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV-infected people who have never received anti-HIV therapy be treated with a triple drug regimen (commonly called combination antiretroviral therapy, cART). Since the introduction of cART, morbidity and mortality among HIV-infected patients has been dramatically reduced. However, metabolic, skeletal, and cardiovascular diseases have been increasingly reported among HIV-infected patients and may be attributable, in part, to the direct effects of cART. Much of our understanding of the development of these diseases, risk factors, and consequences of these disorders has been derived from clinical studies of HIV-infected persons receiving older antiretroviral agents. A5260s was designed to examine the contributions of HIV-disease related factors and impact of newer antiretroviral drugs on the development of metabolic (such as blood vessels, blood sugar, cholesterol), skeletal, and cardiovascular diseases in people who have never received anti-HIV therapy. A5260s is a prospective substudy of a phase III randomized clinical trial A5257 (see ClinicalTrials.gov identifier: NCT00811954). A5257 was designed to look at different combinations of anti-HIV drugs that do not contain the medication efavirenz (EFV) and how well these drug combinations work to decrease the amount of HIV in the blood and to allow immune system recovery in people who have never received anti-HIV therapy. A5257 also examined drug tolerability and safety for the various drug combinations.

Measurement of Adherence to ART in HIV-Infected Children in Uganda (The CHARTA Study)
HIVHIV InfectionsThis study will compare methods of determining whether HIV-infected children take their medications.

Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity...
HIV InfectionPHPC-02 is a phase II, randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific T cell precursors with high proliferative capacity (PHPC) in HIV-1-infected individuals, and whether the quantity of PHPC correlates with the viral load set point following analytical treatment interruption (ATI). Subjects will be randomized to receive either DermaVir Patch (8 subjects per cohort) or DermaVir Patch Placebo (8 subjects per cohort) every four weeks for three applications while receiving maximally suppressive HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks.